The table below shows TransMedics Group, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Q3 2024
Q2 2024
Revenue
$173.93M
$143.82M
$157.37M
$143.54M
$108.76M
$114.31M
Cost of revenue
$72.77M
$59.25M
$60.78M
$55.31M
$47.92M
$45.04M
Gross profit
$101.16M
$84.58M
$96.59M
$88.23M
$60.84M
$69.26M
R&D
$24.88M
$15.26M
$15.93M
$17.16M
$14.27M
$13.86M
TMDX annual revenue (10-K history)
TransMedics Group, Inc. reported annual revenue of $605.49M for fiscal year 2025. That is up 37.1% from $441.54M in fiscal 2024. Over the 8 fiscal years shown, annual revenue grew from $13.02M (FY 2018) to $605.49M. Figures come from the company's audited annual reports as filed with the SEC.